Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Liabilities (2016 - 2025)

Spyre Therapeutics' Total Liabilities history spans 11 years, with the latest figure at $62.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 31.03% year-over-year to $62.5 million; the TTM value through Dec 2025 reached $62.5 million, down 31.03%, while the annual FY2025 figure was $62.5 million, 31.03% down from the prior year.
  • Total Liabilities reached $62.5 million in Q4 2025 per SYRE's latest filing, up from $49.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $253.6 million in Q2 2023 to a low of $18.8 million in Q1 2023.
  • Average Total Liabilities over 5 years is $61.6 million, with a median of $55.6 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: surged 1024.5% in 2023, then tumbled 75.68% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $26.0 million in 2021, then decreased by 19.8% to $20.8 million in 2022, then skyrocketed by 251.69% to $73.3 million in 2023, then rose by 23.73% to $90.7 million in 2024, then crashed by 31.03% to $62.5 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Total Liabilities are $62.5 million (Q4 2025), $49.5 million (Q3 2025), and $83.1 million (Q2 2025).